MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EDAP stock logo

EDAP

Edap Tms S.a.

$3.39
-0.14
 (-3.97%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  127.064M
Shares Outstanding:  29.148M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Ryan Rhodes
Full Time Employees:  310
Address: 
Parc d’Activites la Poudrette-Lamartine
Vaulx-en-Velin
69120
FR
Website:  https://www.edap-tms.com
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company’s proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/15 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue60,42364,11570,745.224
Gross Profit24,41126,55630,093.829
EBITDA-18,388-15,928-21,782.191
Operating Income-19,813-20,534-25,208.760
Net Income-21,178-19,018-29,336.493

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets91,54886,06367,235
Total Liabilities34,62545,16750,712
Total Stockholders Equity56,92340,89616,523
Total Debt8,42413,9202,067
Cash and Cash Equivalents43,47129,83617,407

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-14,678-13,584-13,948.854
Capital Expenditure-4,296-4,101-4,858.378
Free Cash Flow-18,974-17,685-18,807.233
Net Income-21,178-19,0180
Net Change in Cash-19,665-13,635-26,294.885

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)124,002.528Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)133,356.110Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)128,643.842Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-22,922.088Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-21,314.336Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-22,112.114Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)3,727.405Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,096.920Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)3,910.833Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)66,256.976Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)71,254.778Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)68,736.921Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.100Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.110Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.100Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.7
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-3.78
?Enterprise Value
 (TTM)
: 
121.245M  ?EV/FCF
 (TTM)
: 
-5.73
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.12  ?ROIC
 (TTM)
: 
-0.49
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
1.43
?P/B
 (TTM)
: 
5.71  ?Current Ratio
 (TTM)
: 
1.54

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EDAP Intrinsic Value

Common questions about EDAP valuation

Is Edap Tms S.a. (EDAP) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Edap Tms S.a. (EDAP) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EDAP a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EDAP trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EDAP’s P/E ratio?

You can see EDAP’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EDAP?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EDAP a good long-term investment?

Whether EDAP fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EDAP

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-3.97
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 1.21   Year High: 5.05
Price Avg 50: 4.17   Price Avg 200: 2.72
Volume: 50413   Average Volume: 49203

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for EDAP

Relevant news

Edap Tms (NASDAQ:EDAP) vs. Paradigm Medical Industries (OTCMKTS:PDMI) Head-To-Head Analysis
06-03-2026 02:08
Edap Tms (NASDAQ:EDAP) vs. Paradigm Medical Industries (OTCMKTS:PDMI) Head-To-Head Analysis
Critical Analysis: Edap Tms (NASDAQ:EDAP) & OrthoPediatrics (NASDAQ:KIDS)
17-02-2026 02:10
Critical Analysis: Edap Tms (NASDAQ:EDAP) & OrthoPediatrics (NASDAQ:KIDS)

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read